Best Hospitals for Immunotherapy for Cancer in Chennai, India

Cancer immunotherapy is a class of treatments that modulates or augments the immune system's capacity to recognize tumor-associated antigens (TAAs) and mount a sustained cytotoxic response against malignant cells. Unlike conventional chemotherapy — which exerts cytotoxic effects on all rapidly dividing cells — immunotherapy is designed to achieve tumor-selective killing while generating immunological memory capable of preventing relapse. The principal biological targets include immune checkpoint proteins (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3), tumor-infiltrating lymphocyte (TIL) pathways, and surface antigens uniquely expressed on cancer cells such as CD19, CD20, HER2, and EGFR. Understanding which pathway to target requires comprehensive molecular tumor profiling, making precision diagnostics an inseparable component of modern immunotherapy.

• ELIGIBILITY CRITERIA:
• Patients with histologically or cytologically confirmed solid tumors or hematologic malignancies for whom immunotherapy has regulatory approval or strong Level 1 evidence (e.g., NSCLC, melanoma, bladder cancer, RCC, HCC, MSI-H colorectal cancer, triple-negative breast cancer, classical Hodgkin lymphoma, diffuse large B-cell lymphoma)
• Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or large B-cell lymphoma who have failed ≥2 prior lines of systemic therapy (CAR-T eligibility)
• ECOG Performance Status 0–2 (patients with PS 3–4 are generally not candidates for aggressive immunotherapy unless performance decline is directly disease-related and reversible)
• Adequate organ function: serum creatinine ≤1.5× ULN, ALT/AST ≤2.5× ULN (≤5× ULN for hepatic metastases), absolute neutrophil count ≥1,500/µL, platelet count ≥75,000/µL
• +19 more

Checkpoint Inhibitor Therapy (ANTI-PD-1 / PD-L1 / CTLA-4):

This is the most widely deployed immunotherapy modality. Monoclonal antibodies block inhibitory immune checkpoints, releasing cytotoxic T-cell brake mechanisms:

• Anti-PD-1 agents: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Dostarlimab (Jemperli)
• Anti-PD-L1 agents: Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Avelumab (Bavencio)
• Anti-CTLA-4 agents: Ipilimumab (Yervoy), Tremelimumab (Imjudo)
• Dual checkpoint blockade (nivolumab + ipilimumab): Standard of care for metastatic melanoma, MSI-H colorectal cancer, malignant pleural mesothelioma, and selected NSCLC subgroups
• Novel checkpoint targets in clinical use and advanced trials: LAG-3 (relatlimab — FDA-approved in combination with nivolumab for melanoma), TIM-3, TIGIT, VISTA

Administration: IV infusion every 3–6 weeks; most protocols are outpatient-based, with cycle durations of 6 months to 2 years depending on disease response and toxicity profile.

PHASE 1 — Pre-treatment Evaluation (WEEKS 1–3, OFTEN Completable REMOTELY):

• Upload all existing pathology reports, imaging (PET-CT, MRI, CT), surgical/biopsy records, and prior treatment summaries to GAF Healthcare's secure patient portal for remote multidisciplinary tumor board (MDT) review
• GAF Healthcare coordinates an initial teleconsultation with a board-certified medical oncologist specializing in your cancer type within 48–72 hours
• Biomarker testing is arranged: if tissue blocks are available, NGS/CGP and IHC panels are initiated immediately; liquid biopsy (ctDNA) may substitute or supplement if tissue is inadequate
• Baseline organ function labs, cardiac evaluation (ECHO, ECG), and autoimmune/endocrine screening are scheduled upon arrival
• Medical visa (India: e-Medical Visa, processed in 3–5 business days) or UAE entry documentation is arranged by GAF Healthcare's concierge team

PHASE 2 — Arrival AND Institutional Workup (DAYS 1–5 IN COUNTRY):